Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Jeana Keith

Nurse Practitioner, Primary Care Somerset, KY Nurse Practitioner

NPI 1780448928 CMS profile 11599567

6470 S Highway 27, Somerset, KY 42501

Open in the dashboard

General payments

$816

46 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeana Keith of Somerset, KY is reported in the CMS Open Payments database as having received $816 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $378 25
2024 General $438 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeana Keith
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Jeana Keith were reported at $378. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Jeana Keith Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $0 $163 $53–$481 $160
2024 $438 $176 $54–$511 $164
2025 $378 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Astellas Pharma US Inc $182 6 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $151 14 payments
  3. AbbVie, Inc. $77 4 payments
  4. Novo Nordisk Inc $62 3 payments
  5. AstraZeneca Pharmaceuticals LP $54 3 payments
  6. Novartis Pharmaceuticals Corporation $45 3 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $35 2 payments
  8. Lilly USA, LLC $33 2 payments
  9. Pfizer Inc. $32 2 payments
  10. Kestra Medical Technology Services, Inc. $30 1 payment
  11. Other $115 6 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $816 46 payments
Products named General payments · program years 2024–2025
  1. Veozah $182 6 payments
  2. LifeVest $151 14 payments
  3. QULIPTA $58 3 payments
  4. LEQVIO $45 3 payments
  5. AIRSUPRA $39 2 payments
  6. Kerendia $35 2 payments
  7. UBRELVY $33 2 payments
  8. MOUNJARO $33 2 payments
  9. VYNDAQEL $32 2 payments
  10. Assure WCD $30 1 payment
  11. Other $210 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,127

Median for Nurse Practitioner: 389

Drug cost

$122,548

Median for Nurse Practitioner: $21,885

Branded share of claims

22.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 26 $25,263
Eliquis Apixaban Brand 25 $23,695
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $18,561
Ozempic Semaglutide Brand 14 $12,992
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 15 $11,490
Jardiance Empagliflozin Brand 16 $9,688
Linzess Linaclotide Brand 14 $7,774
Duloxetine Hcl Generic 28 $1,366
Ventolin Hfa Albuterol Sulfate Brand 18 $1,229
Ezetimibe Generic 16 $957

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $182
$182 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $39
$39 — —
QULIPTA
  • AbbVie, Inc. $34
$34 — —
MOUNJARO
  • Lilly USA, LLC $33
$33 26 —
YUPELRI
  • Mylan Specialty L.P. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record